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1  |  INTRODUC TION
HGPS is a rare disease that causes accelerated aging in children. 
Disease symptoms appear soon after birth and include skin abnor-
malities, alopecia, osteoporosis, and osteolysis with bone resorption 
at clavicles, phalanges and mandible, generalized lipodystrophy, and 
cardiovascular disorders leading to early death (Filgueiras-Rama 
et al., 2018; Gonzalo et al., 2017; Hamczyk et al., 2018). Searching 
therapeutic strategies for HGPS is still a challenge. Although an on-
going clinical trial exploiting a farnesyltransferase inhibitor elicited 
several positive results (Gordon et al., 2018), significant increase 
in life span and slowdown of organismal aging were not achieved. 
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Abstract
Hutchinson–Gilford progeria syndrome (HGPS) causes premature aging in children, 
with	adipose	tissue,	skin	and	bone	deterioration,	and	cardiovascular	 impairment.	 In	
HGPS cells and mouse models, high levels of interleukin-6, an inflammatory cytokine 
linked to aging processes, have been detected. Here, we show that inhibition of inter-
leukin-6 activity by tocilizumab, a neutralizing antibody raised against interleukin-6 re-
ceptors, counteracts progeroid features in both HGPS fibroblasts and LmnaG609G/G609G 
progeroid mice. Tocilizumab treatment limits the accumulation of progerin, the toxic 
protein produced in HGPS cells, rescues nuclear envelope and chromatin abnormali-
ties,	and	attenuates	the	hyperactivated	DNA	damage	response.	In	vivo	administration	
of tocilizumab reduces aortic lesions and adipose tissue dystrophy, delays the onset of 
lipodystrophy and kyphosis, avoids motor impairment, and preserves a good quality 
of life in progeroid mice. This work identifies tocilizumab as a valuable tool in HGPS 
therapy and, speculatively, in the treatment of a variety of aging-related disorders.
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Moreover,	poor	quality	of	life	characterizes	HGPS	due	to	very	early	
onset and progressive worsening of osteoporosis, lipodystrophy, ar-
ticular impairment, and cardiovascular disorders, which are barely 
improved by current treatments (Gordon et al., 2018).
The molecular defect causing HGPS is an heterozygous mutation 
in the LMNA gene, which encodes five A type lamins by alternative 
splicing,	including	lamins	A	and	C	(Eriksson	et	al.,	2003).	Most	HGPS	
cases	are	linked	to	the	c.1824C>T;p.G608G	silent	mutation	in	LMNA 
gene, which activates an aberrant splicing (De Sandre-Giovannoli 
et al., 2003; Eriksson et al., 2003). The aberrantly spliced gene 
product is translated as progerin, a truncated prelamin A form that 
undergoes farnesylation at its C-terminus as wild-type prelamin A, 
but cannot be fully processed. Thus, progerin is maintained in HGPS 
cells as a permanently farnesylated protein precursor (Eriksson et al., 
2003) and causes chromatin disorganization, aberrant nuclear lam-
ina interaction with transcription factors and chromatin-binding pro-
teins, upregulation of p21 and geroconversion of cells (Kreienkamp 
et	al.,	2016,	2018;	Mattioli	et	al.,	2018).	Further,	altered	nucleo-cy-
toskeleton interplay involving tubulins and defective ion channel ex-
pression or activity have been shown in progeroid cells (Larrieu et al., 
2018; Zironi et al., 2018). The outcome of such an altered scenario 




Progerin effects on the secretome have been observed in sev-
eral	 preclinical	 models	 of	 HGPS	 (Gonzalo	 &	 Coll-Bonfill,	 2019;	
Kreienkamp	et	al.,	2018;	Osmanagic-Myers	et	al.,	2019;	Osorio	et	al.,	
2012).	In	mice,	it	has	been	demonstrated	that	selective	expression	
of progerin in endothelial cells causes dysregulation of circulating 
molecules and a condition leading to paracrine and profibrotic ef-
fects	(Osmanagic-Myers	et	al.,	2019;	Sun	et	al.,	2020).	Activation	of	
the senescence-associated secretory phenotype (SASP) by endo-
thelium-targeted progerin affected most mouse tissues and induced 
premature aging in the whole organism (Sun et al., 2020). Systemic 
effects	linked	to	aberrant	NF-kB	signaling	and	interleukin	6	(IL6)	in-
crease have been observed in LmnaG609G/G609G and Zmpste24−/− pro-
geroid mice featuring progerin or prelamin A accumulation, while 
anti-inflammatory	drugs	have	been	shown	to	extend	life	span	(Osorio	
et	al.,	2011,	2012).	Moreover,	recent	studies	showed	that	aberrant	
activation of JAK-STAT signaling occurs in HGPS cells and animal 
models	and	triggers	SASP	with	increase	of	IL6	and	IL8	(Griveau	et	al.,	
2020;	Liu	et	al.,	2019).	Intriguingly,	prelamin	A-dependent	SASP	ac-
tivation,	 including	 IL6	 hypersecretion,	 has	 been	 also	 observed	 in	
human vascular smooth muscle cells undergoing calcification (Liu 
et al., 2013), a condition that is found in HGPS and contributes to 
disease severity (Gordon et al., 2016).
IL6	 behaves	 as	 a	 pro-inflammatory	 cytokine,	 with	 features	 of	
anti-inflammatory	 molecule	 under	 certain	 conditions.	 In	 particu-
lar,	 canonical	 IL6	 signaling,	 which	 relies	 on	 membrane-bound	 re-
ceptor	alpha	(IL6Ra)	and	on	the	ubiquitous	receptor	GP130	(Baran	
et al., 2018), triggers anti-inflammatory and pro-regenerative path-
ways, and it is restricted to cells harboring the receptor on their 
membrane, mainly hepatocytes and macrophages (Baran et al., 
2018).	 Conversely,	 through	 the	 soluble	 IL6	 receptor	 (sIL6R),	 IL6	




self-fueling circle activated by various stress conditions (Fang et al., 
2014;	Rodier	et	al.,	2009;	Storci	et	al.,	2019),
In	 the	 clinical	 practice,	 an	 anti-IL6	 receptor	 antibody	 (tocili-
zumab) is widely used to treat the abnormal inflammatory response 
that occurs in autoimmune diseases as rheumatoid arthritis and it 
is well tolerated by patients, even at very young age (Emery et al., 
2019;	Mallalieu	et	al.,	2019;	Mihara	et	al.,	2011).	The	positive	effect	
of	the	antibody	relies	on	neutralization	of	IL6	activity	through	com-
petition	with	 soluble	 and	membrane-bound	 IL6	 receptors	 (Mihara	
et al., 2011). Efficacy of antibody treatment has been demonstrated 
particularly in the osteoarticular system in both murine experimen-
tal	models	(Kamiya	et	al.,	2019)	and	patients	(Safy-Khan	et	al.,	2020).	
We reasoned that tocilizumab treatment could be beneficial in HGPS 
by	reducing	IL6-related	progeroid	features	and	tested	this	hypothe-
sis in cultured HGPS fibroblasts, LmnaG609G/G609G mouse cells, and in 
vivo in LmnaG609G/G609G	mice	(Osorio	et	al.,	2011,	2012;	Zaghini	et	al.,	
2020). We show here that tocilizumab counteracts aberrant differ-
entiation of adipocytes and osteoblasts from LmnaG609G/G609G pro-
geroid mice, improves adipose tissue dystrophy, aorta histological 
lesions, and skeletal deterioration, and positively impacts the overall 
condition of progeroid mice, while unexpectedly reducing progerin 
accumulation and its deleterious effects in mouse and human pro-
geria cells.
2  |  RESULTS
2.1  |  IL6 secretion is increased in HGPS cells
Consistent with previous studies (Bidault et al., 2020; Liu et al., 
2019),	 we	 observed	 that	 IL6	 secretion	 is	 increased	 in	 HGPS	 fi-
broblasts carrying the classical G608G LMNA mutation and also 
in	 fibroblasts	 from	 Mandibuloacral	 Dysplasia,	 another	 LMNA-
linked progeroid syndrome (Cenni et al., 2018; Filesi et al., 2005) 
(Figure 1a and Figure S1a). Further, the LMNA delta 50 mutation 
causing progerin expression, when transiently expressed in human 
HEK293	cells,	induced	hypersecretion	of	IL6	(Figure	1b).	Although	
overexpression of wild-type LMNA	 elicited	 some	 increase	 in	 IL6	
levels,	much	more	 significant	enhancement	of	 IL6	 secretion	was	
induced	 by	 progerin	 (Figure	 1b)	 as	 well	 as	 by	 Mandibuloacral	
Dysplasia-linked R527H-mutated lamin A (Figure S1B). These re-




did not elicit any promoter activity signal neither in controls nor 
in	HGPS	fibroblasts	 (Figure	1D).	Moreover,	NF-kB	promoter	was	
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hyperactivated in HGPS cells (Figure 1e). We further observed 
that	activated	STAT3,	a	main	effector	of	 IL6	signaling,	was	accu-
mulated to a significantly higher extent in the nucleus of HGPS 
fibroblasts	relative	to	control	fibroblast	nuclei	(Figure	1f).	In	fact,	
both Tyrosine 705 and Serine 727 STAT3 phosphorylation were 
increased in HGPS nuclei (Figure 1f).
2.2  |  Tocilizumab counteracts IL6 activity and 
bystander effects and progerin accumulation
In	 this	 context,	 we	 tested	 the	 effects	 of	 the	 neutralizing	 anti-IL6	
receptor antibody tocilizumab in HGPS cells. STAT3 phosphoryla-
tion was significantly inhibited in HGPS fibroblasts subjected to 
F I G U R E  1 IL6	levels	and	activity	are	increased	in	HGPS	cells.	(a)	IL6	secretion	in	culture	media	of	normal	human	dermal	fibroblasts	
(Control)	or	HGPS	fibroblasts	(HGPS)	after	48	h	in	cell	culture.	IL6	levels	were	measured	by	ELISA.	(b)	IL6	secretion	in	culture	media	of	






graph as arbitrary units (a.u.). Scale bar, 10 µm Three biological replicates were used in all analyses (panels a, b, d, e, f), except in qRT-PCR 
(panel c, six biological replicates). Data are reported as means ± SEM. Statistically significant differences are indicated (*p < 0.05, **p < 0.01, 
***p < 0.001)
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tocilizumab	treatment	(Figure	2a).	In	particular,	while	tocilizumab	did	
not inhibit STAT3 phosphorylation on Tyrosine 705, phosphoryla-
tion of Serine 727, which is required for STAT3 transactivation activ-
ity (Wakahara et al., 2012), was significantly reduced by tocilizumab 
treatment (Figure 2a), which demonstrated its inhibitory activity in 
human	dermal	 cells.	 Since	 IL6	 activity	 is	 linked	 to	hyperactivation	
of	 the	DNA	 damage	 sensor	 γ-H2AX, which is increased in HGPS 
cells,	we	hypothesized	 that	 inhibition	of	 IL6	could	 reduce	γ-H2AX 
amount.	Interestingly,	in	HGPS	cells	subjected	to	tocilizumab,	signifi-
cantly lower amount of γ-H2AX was detected (Figure 2b).
Moreover,	 while	 HGPS	 fibroblast	 conditioned	 medium	 trig-
gered γ-H2AX even in normal human dermal fibroblasts, tocili-
zumab treatment significantly reduced HGPS secretome-induced 
γ-H2AX accumulation (Figure 2c). The latter observation showed 
the efficacy of the proposed treatment on the bystander effect 
of	 HGPS	 cellular	 secretome	 and	 in	 particular	 of	 secreted	 IL6.	
Importantly,	 in	 HGPS-conditioned	 normal	 dermal	 fibroblasts,	
Senescence-Associated beta-Galactosidase (SA-βGal) staining 
was significantly increased, while tocilizumab prevented SA-βGal 
increase (Figure 2d). The latter result showed the inhibitory ef-
fect of tocilizumab on secretome-induced cellular senescence. 
Consistently, in HGPS fibroblasts, tocilizumab treatment elicited 
downregulation of the senescence marker p21 (Figure 2e), which 
is	upregulated	in	HGPS	(Mattioli	et	al.,	2018).	These	results	sug-
gested inhibition of cellular senescence and a general improve-
ment of HGPS cellular phenotype upon tocilizumab treatment. 
In	 agreement	with	 this	 observation,	 significant	 improvement	 in	
nuclear shape, measured by the contour ratio algorithm, was ob-
served in HGPS fibroblasts treated with tocilizumab, while lamin 
A/C immunofluorescence signal was not significantly affected 
(Figure	 2f).	 Moreover,	 chromatin	 organization	 was	 improved	
in tocilizumab-treated cells, as also detectable from recovery 
of facultative heterochromatin areas (Figure 2f, arrowheads) 
(Lattanzi et al., 2007). Since nuclear dysmorphism has been di-
rectly correlated with the amount of progerin in the nuclear lam-
ina (Columbaro et al., 2005), we decided to test progerin levels 
and localization in tocilizumab-treated cells. Sharp progerin la-
beling was detected in untreated HGPS fibroblasts (Figure 2g). 
Interestingly,	 in	 HGPS	 cells	 subjected	 to	 tocilizumab,	 progerin	
fluorescence signal was diminished even in residual dysmorphic 
nuclei, where the mutated protein formed nuclear aggregates, 
while	reduction	in	MFI	was	observed	in	the	whole	cell	population	
(Figure 2g). Biochemical analysis confirmed significant reduc-
tion of progerin amount in HGPS fibroblasts subjected to tocili-
zumab treatment (Figure 2h). Although reduced lamin A and C 
amount was also detected in antibody-treated cells, tocilizumab 
determined a significant increase in lamin A to progerin ratio 
(Figure 2h), which is relevant to the improvement of HGPS cellu-
lar phenotype (Pellegrini et al., 2015).
2.3  |  Effects of tocilizumab in muscle, tendons, and 
bone of LmnaG609G/G609G mice
Based on these results, we treated progeroid mice with tocilizumab 
starting	at	weaning	(4	weeks	of	age)	and	evaluated	antibody	effects	
in various tissues known to be affected in this mouse model (Zaghini 
et al., 2020). Figure 3 shows the outcome of tocilizumab treatment 
in the musculoskeletal system of LmnaG609G/G609G	 mice.	 Muscle	
fibers did not show irregular shape in progeroid mice (Figure 3a). 
However, in skeletal muscle of vehicle-treated LmnaG609G/G609Gmice 
at 100 days of age, altered nuclear shape was observed by lamin A/C 
labeling	of	muscle	cryosections	(Figure	3a).	Nuclear	shape	was	sig-
nificantly improved in muscle from age-matched tocilizumab-treated 
LmnaG609G/G609G mice, as measured according to the contour ratio al-
gorithm in myonuclei observed by electron microscopy (Figure 3b,c). 
In	 fact,	 ultrastructural	 analysis	 showed	 severe	 nuclear	 morpho-
logical abnormalities in LmnaG609G/G609G mouse muscle consisting 
of nuclear envelope folding and loss of peripheral heterochromatin, 
which were recovered in muscle from tocilizumab-treated progeroid 
mice	 (Figure	 3c).	 On	 the	 other	 hand,	 nuclear	 positioning	 and	 sar-
comere ultrastructural organization were not altered in progeroid 
F I G U R E  2 Tocilizumab	reduces	IL-6	dependent	STAT3	and	γ-H2AX activation and counteracts cellular senescence. (a) Western blot 
analysis of STAT3 phosphorylated on Tyrosine 705 (P-STAT3 Y705) or Serine 727 (P-STAT3 S727), STAT3, in untreated or tocilizumab-
treated	HGPS	fibroblasts	(T).	Tocilizumab	dosage	(µg/ml	culture	medium)	is	indicated	in	the	upper	row.	In	the	graphs	and	all	the	following	
panels:	NT,	0	µg/ml	tocilizumab;	T,	100	µg/ml	tocilizumab.	(b)Western	blot	analysis	of	γ-H2AX in HGPS fibroblasts and (c) in normal 
human dermal fibroblasts subjected to conditioning with control fibroblasts (ctrl) or HGPS fibroblast medium (HGPS). β-tubulin and β-actin 









Densitometry of immunoblotted protein bands is reported in the upper graph. Lamin A to progerin ratio (calculated on mean densitometric 
values	of	each	sample)	is	shown	in	the	lower	graph.	Three	biological	replicates	were	used	in	all	analyses.	In	panels	(a,	b,	c,	e,	h),	densitometry	
of immunoblotted protein bands is plotted in the graphs in arbitrary units (a.u.). Data are reported as means ± SEM. Statistically significant 
differences are indicated (*p < 0.05, **p < 0.01). 100 µg/ml tocilizumab were applied in all experiments
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mice	 (Figure	 3a,c).	Moreover,	 as	 observed	 in	 cultured	HGPS	 cells,	
in vivo tocilizumab administration reduced progerin accumulation 
in LmnaG609G/G609G	muscle	 tissue	 (Figure	3d).	Noteworthy,	 in	prog-
eroid mouse muscle the lamin-binding partner emerin was reduced, 
while tocilizumab restored emerin amount (Figure 3d). We further 
investigated the muscle-specific oxidative stress responsive protein 
Ankrd2	(Cenni	et	al.,	2019).	In	LmnaG609G/G609G mouse muscle, Ankrd2 
amount was significantly reduced, while tocilizumab treatment in-
creased Ankrd2 levels to a condition comparable to wild-type mouse 
tissue (Figure 3d).
Motor	 function	 in	 progeria	 might	 be	 also	 affected	 by	 defects	
in tendons. By ultrastructural analysis, misshapen nuclei were also 
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detected in tendons of LmnaG609G/G609G progeroid mice (Figure 3e). 
In	 particular,	 enlargement	 of	 perinuclear	 space	 with	 formation	 of	
vesicles was consistently observed in the vast majority of examined 
tendon nuclei (Figure 3e). These nuclear defects were abolished in 
mice subjected to tocilizumab (Figure 3e).
Then, we analyzed bone phenotype in LmnaG609G/G609G mice by 
microCT scan analysis and observed an altered structure of femur 
condyles	 (Figure	 3f).	 In	 age-matched	 tocilizumab-treated	 pro-
geroid mice, bone trabecular organization was improved (mean 
BV/BT	0,82	in	tocilizumab-treated	vs	0.42	in	untreated	progeroid	
mice,	 Figure	 3f).	 Moreover,	 femur	 biomechanical	 length,	 which	
was significantly reduced in LmnaG609G/G609Gmice, increased in 
tocilizumab-treated animals relative to untreated littermates 
(Figure 3g). However, trabecular thickness (Figure 3h) and other 
bone parameters were not significantly improved by tocilizumab 
treatment.
In	 cultured	 cells	 derived	 from	 LmnaG609G/G609Gmouse muscle 
or	 bone,	 tocilizumab	 treatment	 also	 elicited	 positive	 effects.	 In	
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progeroid mouse myoblasts, nuclear shape and chromatin orga-
nization were severely affected (Figure S2A). However, in myo-
blasts subjected to tocilizumab, nuclear shape was improved and 
a trend toward recovery of heterochromatin clusters was ob-
served (Figure S2A). All these effects were related to decrease 
in	 progerin	 levels	 (Figure	 S2B).	 Moreover,	 as	 reported	 above	
for HGPS cells (Figure 2), in vitro tocilizumab administration 
elicited lower γ-H2AX and p21 levels in progeroid mouse myo-
blasts	 (Figure	S2B),	suggesting	rescue	of	DNA	damage	response	
and senescence pathways. Since previous studies had reported 
altered differentiation rate of laminopathic bone precursors 
(Avnet	 et	 al.,	 2011;	 Scaffidi	 &	Misteli,	 2008;	 Strandgren	 et	 al.,	
2015; Vidal et al., 2012), we established osteoblast cultures from 
LmnaG609G/+ mouse bone and checked the differentiation rate in 
the presence or absence of tocilizumab. Higher differentiation 
rate was observed in LmnaG609G/+ osteoblasts, compared to osteo-
blasts derived from Lmna+/+ mouse bone (Figure S2C). However, 
tocilizumab treatment of progeroid osteoblasts restored a dif-
ferentiation rate comparable to wild-type cells, as determined 
by measuring Alizarin red staining of cell cultures at 21 days in 
differentiation medium (Figure S2C). These results indicated that 
progeroid myoblasts and osteoblasts feature cellular abnormali-
ties independently of the whole organism condition, yet at least 
in	 part	 determined	 by	 hyperactivation	 of	 IL6.	 As	 a	whole,	 data	
here reported show that tocilizumab counteracts progerin effects 
in cells from the musculoskeletal apparatus.
2.4  |  Improvement of cardiovascular phenotype in 
tocilizumab-treated LmnaG609G/G609Gmice
Aorta is a main target of HGPS pathology (Hamczyk & Andres, 
2019;	Hamczyk,	del	Campo,	et	al.,	2018;	Hamczyk,	Villa-Bellosta,	
et al., 2018). Histological analysis of LmnaG609G/G609G mouse aorta 
sections showed a severe phenotype with loss of cellularity and 
myxoid	 degeneration	 (Figure	 4a).	 In	 LmnaG609G/G609G mice, toci-
lizumab	 treatment	 reduced	 aorta	 degeneration	 (Figure	 4a	 and	
Table S1).
As	 previously	 reported	 (Del	 Campo	 et	 al.,	 2019;	 Villa-Bellosta	
et al., 2013), the number of smooth muscle cells was dramatically 
reduced in LmnaG609G/G609G	mouse	 aorta	 (Figure	4b).	However,	 to-
cilizumab administration led to a significant increase in smooth 
muscle	 cell	 number	 (Figure	 4b).	 As	 observed	 in	 skeletal	 muscle,	
in vivo tocilizumab administration elicited reduction of progerin 
levels in myocardium, while lamin C and emerin amount were not 
changed	(Figure	4c).	In	progeroid	mice,	we	observed	cardiomyocyte	
hypertrophy	 (Figure	4d).	 In	 fact,	mean	cross-sectional	diameter	of	
cardiomyocytes from LmnaG609G/G609G mice aged 3 months was com-
parable to that measured in wild-type littermates aged 13 months 
(Figure	 4d),	 despite	 wild-type	 mice	 weight	 reached	 24	 g,	 while	
LmnaG609G/G609Gmice	maximum	weight	was	below	18	grams.	In	myo-
cardium from tocilizumab-treated LmnaG609G/G609G animals, cardio-
myocyte mean diameter was significantly reduced, suggesting a less 
severe	heart	disorder	(Figure	4d,e).
2.5  |  Improvement of adipose tissue phenotype in 
tocilizumab-treated progeroid mice
Fat loss is rapid in LmnaG609G/G609G mice, and almost all white adipose 
tissue is quickly lost around 5 weeks (Zaghini et al., 2020), so that 
evaluation of chronic treatment starting at weaning is not possible. 
Thus, to test the effect of tocilizumab on adipose tissue, we analyzed 
subcutaneous fat from control and tocilizumab-treated LmnaG609G/+ 
mice, which show slower progression of lipodystrophy, detectable at 
week 16 of age and progressing to complete atrophy of subcutane-
ous	 fat	at	week	43	 (Zaghini	et	al.,	2020).	A	dystrophic	phenotype	
with high adipocyte diameter variability was observed in white fat 
from	untreated	progeroid	mice	aged	200	days	(Figure	5a).	In	adipose	
tissue from tocilizumab-treated LmnaG609G/+mice, a more homogene-
ous adipocyte size and an overall increase in adipocyte mean diam-
eter	were	observed	(Figure	5a).	Impaired	terminal	differentiation	of	
adipocytes was observed by ultrastructural analysis in tissue from 
untreated LmnaG609G/+mice (Figure 5b), while fusion of lipid droplets 
appeared to be increased in tocilizumab-treated mouse adipose tis-
sue (Figure 5c). As quantitative analysis confirmed the increase of 
F I G U R E  3 Effects	of	tocilizumab	in	muscle,	tendons	and	bone	of	LmnaG609G/G609G	mice.	(a)	Immunofluorescence	staining	of	lamin	
A/C (green) in Lmna+/+ or LmnaG609G/G609Gmice	(mean	age	100	days),	left	untreated	(NT)	or	treated	(T)	with	tocilizumab.	Muscle	fibers	are	
delineated by perlecan staining (red). Higher magnification of nuclei labeled by lamin A/C antibody is shown in the insets. Scale bars, 10 µm. 
(b) Contour ratio of muscle nuclei in tissue from three different Lmna+/+ or LmnaG609G/G609G	vehicle-treated	(NT)	or	tocilizumab-treated	mice	
(T). The analysis was performed in 100 nuclei per sample observed by electron microscopy. (c) Transmission electron microscopy analysis 
of	skeletal	muscle	nuclei	from	vehicle-treated	(NT)	or	tocilizumab-treated	LmnaG609G/G609Gmice (T). Scale bars, 1 µm. (d) Western blot 
analysis of progerin, Ankrd2 and emerin in muscle from Lmna+/+ or LmnaG609G/G609G	mice,	vehicle-treated	(NT)	or	treated	with	tocilizumab	
(T). Tubulin was used as a loading control. Densitometry of immunoblotted protein bands is plotted in the graphs in arbitrary units (a.u.). (e) 
Transmission electron microscopy analysis of tendons from LmnaG609G/G609G	mice	subjected	to	vehicle	(NT)	or	tocilizumab	(T).	Cell	nuclei	of	
LmnaG609G/G609G	mouse	tendons	show	vesicles	in	the	perinuclear	space	(NT,	round	vesicles),	which	are	not	observed	in	tocilizumab-treated	
mice. Heterochromatin areas appear also disorganized in progeroid mouse tendon nuclei, while recovery of heterochromatin at the nuclear 
periphery is observed in tocilizumab-treated LmnaG609G/G609G mouse tissue. The analysis was performed in 50 nuclei per sample. Scale bars, 
1 µm. (f) microCT scans of femur from Lmna+/+, untreated LmnaG609G/G609G	(NT)	or	tocilizumab-treated	LmnaG609G/G609G	mice.	Mean	values	of	
relative	bone	volumes	(bone	volume/tissue	volume	(BV/TV))	of	the	corresponding	samples	are	indicated	under	each	picture.	(g)	Mean	femur	
biomechanical length (length) and (h) trabecular thickness values (Tb.th) measured in groups of three Lmna+/+, untreated LmnaG609G/G609G 
(NT)	or	tocilizumab-treated	LmnaG609G/G609G mice (T). Three biological replicates were used in each experiment. Data are reported as 
means ± SEM. Statistically significant differences are indicated (*p < 0.05, **p < 0.01, ***p	<	0.001).	Mean	age	of	mice	(all	males),	100	±	6	days
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F I G U R E  4 Tocilizumab	reduces	aorta	lesions	and	cardiomyocyte	hypertrophy	in	progeroid	mice.	(a)	Aorta	medium	layer	histochemical	
analysis in Lmna+/+ and LmnaG609G/G609G	mice	left	untreated	(NT)	or	treated	with	tocilizumab	(T).	Hematoxylin–eosin	(left	panels)	and	Alcian	
Blue staining (right panels) show loss of cellularity and myxoid degeneration (accumulation of acidic mucopolysaccharides) in aorta from 
vehicle-treated LmnaG609G/G609Gmice	(NT)	and	rescue	with	tocilizumab	(T).	(b)	Mean	number	of	smooth	muscle	cells	detected	in	aorta	
sections	is	reported	in	the	graph.	(c)	Western	blot	analysis	of	Progerin,	Lamin	C	and	Emerin	in	myocardium	lysates	from	untreated	(NT)	or	
tocilizumab-treated LmnaG609G/G609Gmice (T). GAPDH bands are shown as loading controls. Densitometry of immunoblotted protein bands 
is	plotted	in	the	graphs	in	arbitrary	units	(a.u.).	(d)	Myocardium	sections	from	13	months	old	Lmna+/+ or 3 months old LmnaG609G/G609G mice 
vehicle-treated	(NT)	or	treated	with	tocilizumab	(T).	Extracellular	matrix	surrounding	cardiomyocytes	was	stained	using	an	anti-collagen	VI	
antibody. Bar, 10 µm. (e) Graphs reporting diameter of cardiomyocytes in samples shown in (d). Three biological replicates were used. Data 
are reported as means ± SEM. Statistically significant differences are indicated (*p < 0.05, **p < 0.01)
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adipocyte dimensions in white fat from tocilizumab-treated mice 
(Figure	5d),	we	decided	 to	 test	 the	effect	of	 IL6	neutralization	on	
adipocyte precursors. To this end, we established pre-adipocyte cul-
tures from LmnaG609G/+ white adipose tissue and induced adipogenic 
differentiation	(Pellegrini	et	al.,	2019).	Differentiation	of	LmnaG609G/+ 
pre-adipocytes was reduced, relative to Lmna+/+ pre-adipocytes, and 
significantly improved when tocilizumab was added to differentia-
tion medium (Figure 5e), as demonstrated by enhanced lipid vesi-
cle size (Figure 5f) and increased percentage of differentiating cells 
(Figure 5g).
2.6  |  Phenotype improvement in tocilizumab-
treated progeroid mice
By visual inspection, the phenotype of tocilizumab-treated 
LmnaG609G/G609G mice appeared greatly improved with respect to 
their untreated littermates (Figure 6a). Alopecia was reduced, and 
the quality of the fur, which was typically altered in this mouse 
model	(Zaghini	et	al.,	2020),	was	better	preserved	(Figure	6a).	Motor	
activity was also significantly improved by antibody treatment, as 
demonstrated by open field tests (Figure 6b). Even in very old mice, 
motor	activity	was	preserved	(Figure	6b	and	Movie	S1).	Moreover,	
the onset of kyphosis was delayed in tocilizumab-treated mice 
(Figure 6c). Slowdown of weight loss was also determined by toci-
lizumab	treatment.	In	fact,	while	all	examined	LmnaG609G/G609G mice 
showed significant weight loss between week 6 and 12 of their life, 
weight gain was observed in all tocilizumab-treated progeroid mice 
in the same time frame (Figure 6d). A significant, though moderate, 
life span extension was obtained in LmnaG609G/G609G mice subjected 
to tocilizumab (Figure 6e), while more relevant increase in survival 
was determined in heterozygous mice (Figure 6f).
3  |  DISCUSSION








linked progeroid laminopathies. We further showed that progerin 
expression	 is	sufficient	to	activate	both	IL6	and	NF-kB	promoters,	
demonstrating	 that	 the	 increase	 in	 IL6	 is	 a	 transcriptional	 effect.	
Active	IL6	signaling,	demonstrated	by	nuclear	accumulation	of	phos-
phorylated	STAT3	as	well	as	by	the	activation	of	DNA	damage	sign-
aling elicited by the HGPS secretome in normal dermal fibroblasts, 
appeared to be relevant for HGPS pathogenesis. Thus, the aim of 
our research was to test the potential benefit of treatment with to-
cilizumab	in	HGPS	preclinical	models.	Our	results	show	that	not	only	
tocilizumab	is	able	to	reduce	IL6	signaling	in	HGPS	cells,	but	elicits	
reduction of progerin levels with rescue of nuclear defects caused 
by progerin accumulation. Particularly relevant is the recovery of 
chromatin organization observed in mouse tissues upon in vivo ad-
ministration of tocilizumab, which shows that even early cell intrin-
sic pathogenetic effects are rescued by the antibody. A plethora of 
studies have shown that progerin, as any farnesylated prelamin A 
form, affects nuclear morphology and chromatin organization (Filesi 
et al., 2005; Lattanzi et al., 2007; Pellegrini et al., 2015). Thus, res-
cue of nuclear defects in tocilizumab-treated cells and tissues is an 
obvious	 consequence	 of	 reduced	 progerin	 accumulation.	 In	 previ-
ous studies, stress-induced wild-type prelamin A increase has been 
demonstrated	(Lattanzi	et	al.,	2014;	Mattioli	et	al.,	2018;	Ragnauth	
et	al.,	2010).	It	appears	likely	that	stress	conditions	contribute	to	en-
hanced progerin levels in HGPS cells, while reduced stress signaling 
elicited	by	inhibition	of	IL6	could	reduce	stress-dependent	progerin	
increase.	However,	 a	 relationship	between	progerin	 levels	and	 IL6	
activity has been reported in previously published studies and to-
cilizumab effect on progerin levels could depend on interconnected 
cellular	pathways	involving	JAK/STAT	signaling	(Liu	et	al.,	2019).	On	
the other hand, STAT1-mediated inflammatory response, triggered 
by	replication	fork	stalling	and	damaged	DNA	accumulation	 in	 the	
cytoplasm, has been demonstrated in HGPS cells and a synergistic 
effect	with	STAT3-related	IL6	signaling	on	progeroid	phenotype	ap-
pears	likely	(Kreienkamp	et	al.,	2018).	Interestingly,	any	drug	able	to	
counteract progerin accumulation has been reported to attenuate 
STAT1 activity (Kreienkamp et al., 2018), reinforcing the view of a 
direct link between progerin levels and inflammatory response.
In	vivo	tocilizumab	administration	to	LmnaG609G/G609Gprogeroid 
mice allowed us to show some tissue-specific effects. Tocilizumab 
elicited positive effects in skeletal muscle, including rescue of 
the muscle-specific stress responsive factor Ankrd2 (Cenni et al., 
2019),	 which	 was	 decreased	 in	 progeroid	 muscle.	 This	 result	 is	
particularly relevant, as resolution of oxidative stress and inflam-
mation	could	be	fostered	by	Ankrd2-dependent	NF-kB	inhibition	
(Bean	et	al.,	2014),	with	potential	effects	on	IL6	levels	and	other	
NF-kB	 effectors	 of	 inflammatory	 signaling.	 Reduction	 of	 emerin	
in the skeletal muscle of progeroid mice is a novel finding, which 
could suggest defects in skeletal muscle regeneration associated 
with	 progerin	 expression	 (Capanni	 et	 al.,	 2009;	 Squarzoni	 et	 al.,	
2005). Emerin is the main lamin A/C binding partner, known to play 
a major role in striated muscle and linked to Emery–Dreifuss mus-
cular dystrophy. We previously observed that emerin localization 
at the nuclear membrane is related to its interplay with prelamin 
A	 (Capanni	 et	 al.,	 2009),	 a	mechanism	 that	 could	be	 impaired	 in	
the	presence	of	a	defective	prelamin	A	form	as	progerin.	Of	note,	
concomitant with progerin decrease, emerin levels are rescued in 
skeletal muscle from tocilizumab-treated LmnaG609G/G609G mice, 
while emerin levels are not altered in myocardium of progeroid 
mice nor they are affected by tocilizumab in heart tissue. Further, 
emerin levels are not altered in HGPS fibroblasts, again suggesting 
a tissue-specific deficiency. Given the role of emerin and emerin–
prelamin A interplay in muscle physiology and pathology (Capanni 
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et	al.,	2008,	2009;	Squarzoni	et	al.,	2005),	deeper	understanding	
of emerin fate in HGPS skeletal muscle might provide new insights 
not only into HGPS pathogenesis, but also on aging-associated 
muscle	disorders	as	sarcopenia.	Overall,	altered	nuclear	structure	
and disorganized chromatin here observed both in muscle and ten-
dons, as well as altered expression levels of emerin and Ankrd2 in 
skeletal muscle, indicate an insofar unrecognized condition that 
might contribute to motor function impairment in HGPS (Levy 
et al., 2018).
A limitation of our study is lack of electrophysiological evaluation 
of heart functionality. However, we focused on tissue morphology 
and were able to demonstrate improvement of aorta lesions, including 
smooth muscle cell loss, and amelioration of cardiomyocyte hyper-
trophy in myocardium from tocilizumab-treated mice. Hypertrophy 
of myocardium was previously observed in mouse models expressing 
endothelium-targeted	 progerin	 (Osmanagic-Myers	 et	 al.,	 2019;	 Sun	
et	al.,	2020).	As	SASP	activation	including	IL6	hypersecretion	was	de-
termined in one of those progeroid mouse strains, it is likely that cell 
F I G U R E  5 Tocilizumab	improves	adipose	tissue	phenotype	in	progeroid	mice.	(a)	Light	microscopy	observation	of	semithin	sections	
of subcutaneous adipose tissue from Lmna+/+or LmnaG609G/+	vehicle-treated	(NT)	or	tocilizumab-treated	mice	(T).	Semithin	sections	were	
obtained from epon resin-embedded tissue prepared for electron microscopy analysis. (b, c) Electron microscopy analysis of adipose tissue 
samples shown in (a). Arrows indicate fusing lipid vesicle. (d) Quantitative analysis of adipocyte size in adipose tissue samples shown in (a–c). 
A trend toward wild-type size distribution in tocilizumab-treated LmnaG609G/+mice	is	observed.	(e)	Oil	red	O	staining	of	white	pre-adipocytes	
derived from Lmna+/+ or LmnaG609G/+ mouse subcutaneous fat. (f) Graph showing the distribution of lipid vesicle size. (g) Graph representing 
the percentage of differentiating pre-adipocytes in cell cultures. Data are in arbitrary units (a.u.). Three biological replicates were used. Scale 
bars: (a), 100 µm; (b) 5 µm; (c), 1 µm, (e), 10 µm. Statistically significant differences are indicated (****p < 0.0001)
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F I G U R E  6 Tocilizumab	improves	progeroid	phenotype	and	lifespan	in	progeroid	mice.	(a)	Representative	photographs	of	untreated	(NT)	
and tocilizumab-treated (T) LmnaG609G/G609G	mice	at	80	days	of	age.	(b)	Motility	test	of	untreated	(NT,	n = 3, all males) and tocilizumab-treated 
LmnaG609G/G609G mice (T, n	=	3,	all	males).	In	the	graph	is	reported	the	walking	time	(minutes)	in	a	period	of	30	min.	Differences	at	85	and	
110 days are statistically significant (p	<	0.01).	(c)	Age	at	kyphosis	onset	(days)	of	untreated	(NT,	n = 6, 3 females, 3 males) and tocilizumab-
treated (T, n = 7, 5 females, 2 males) LmnaG609G/G609G mice. Statistically significant difference is indicated (*p < 0.05). (d) Body weight variation 
(%) of untreated and tocilizumab-treated LmnaG609G/G609G	mice	between	6	(6	w)	and	12	weeks	of	age	(12	w).	Mean	values	measured	in	5	mice	
per group (2 females, 3 males) are reported in the upper graph, weight referred to each animal (indicated as 1–10) is reported in the lower 
graphs (left bars, 6 weeks weight; right bars, 12 weeks weight). Statistically significant differences are indicated (**p < 0.01, ****p < 0.0001). 
(e)	Kaplan–Meier	survival	plot	showing	the	increase	in	life	span	of	LmnaG609G/G609G mice treated with tocilizumab (n = 13, 7 females, 6 males) 
as compared with LmnaG609G/G609G untreated littermates (n	=	18,	9	females,	9	males).	p	<	0.05,	log-rank/Mantel-Cox	test.	(f)	Kaplan–Meier	
survival plot showing the increase in life span of LmnaG609G/+ mice treated with tocilizumab (n	=	16,	9	females,	7	males)	as	compared	with	
LmnaG609G/+ untreated littermates (n = 20, 3 females, 17 males). p	<	0.01,	log-rank/Mantel-Cox	test.	The	age	at	50%	survival	(median	survival)	
is indicated next to each graph (d, days)
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extrinsic mechanisms contribute to hypertrophy of cardiac tissue (Sun 
et al., 2020), an hypothesis supported by our results.
Lipodystrophy is a prominent phenotype in all progeroid lami-
nopathies	(Cenni	et	al.,	2018).	None	of	currently	available	drugs	was	
able to counteract adipose tissue loss, either in less severe LMNA-
linked	 lipodystrophies	 (Araujo-Vilar	 &	 Santini,	 2019)	 or	 in	 HGPS	
(Gordon	et	al.,	2018).	On	the	other	hand,	 in	LmnaG609G/G609G mice 
subjected to high fat diet, an impressive life span extension was 
obtained	(Kreienkamp	et	al.,	2019;	Kreienkamp	&	Gonzalo,	2020),	
suggesting a main role of adipose tissue loss in HGPS pathogenesis. 
Thus, amelioration of white adipose tissue condition by tocilizumab 
might contribute to the overall improvement of health status here 
observed in progeroid mice. An application of the antibody to other 
laminopathies featuring lipodystrophy warrants investigation.
Bone phenotype (Gargiuli et al., 2018) was also improved by to-
cilizumab	treatment.	In	fact,	increased	femur	biomechanical	length	
and partial rescue of altered condyle trabecular structure along with 
delay in the onset of kyphosis were observed in antibody-treated 
animals.	 Our	 results	 obtained	 in	 cultured	 LmnaG609G/G609G osteo-
blasts confirmed the aberrantly increased differentiation rate of 
laminopathic osteoblasts previously demonstrated in bone pro-
genitor cells carrying the human progeria G608G LMNA mutation 
(Scaffidi	&	Misteli,	2008)	and	Mandibuloacral	dysplasia	osteoblasts	
(Avnet et al., 2011). We cannot rule out the possibility, suggested in 
other studies, that osteoblast activity could be instead decreased 
in progeroid mice in different bone districts (Strandgren et al., 
2015). However, here we show a differentiation rate comparable 
to wild-type cells in progeria osteoblasts subjected to tocilizumab, 
suggesting	potential	rescue	of	normal	bone	turnover.	Since	IL6	 is	
an osteoclastogenic cytokine and tocilizumab has been shown to 
reduce	 the	 RANKL/OPG	 ratio,	which	 regulates	 osteoclastogene-
sis	 (Kamiya	et	al.,	2019),	we	predict	 that	antibody	administration	




LMNA deficiency (Xiong et al., 2020).
A relevant outcome of tocilizumab treatment was the amelio-
ration	of	motor	 activity	 in	progeroid	mice.	Open	 field	 tests	 showed	
better performance of antibody-treated mice even at advanced age. 
Although skeletal abnormalities and motor impairment do not appear 
as life-threatening features of progeria, they severely impact on pa-
tient quality of life as children affected by progeria can only walk short 
distances	due	to	articular	impairment	(Gordon	et	al.,	2018).	In	this	re-
spect, it is worth to remind that tocilizumab is currently used to treat 
rheumatoid	 arthritis,	where	 the	 antibody	 is	 expected	 to	 reduce	 IL6	
inflammatory	activity	affecting	articular	cartilage	(Mihara	et	al.,	2011).
A main bias in this and almost all previously published studies 
conducted in progeroid mice is failure to identify an obvious cause 
of	 premature	 death	 (Hamczyk	&	Andres,	 2019).	 The	moderate	 in-
crease in life span obtained by tocilizumab administration suggests 
that pathogenetic pathways specifically relevant to animal survival 
were not rescued. For instance, despite amelioration of adipose 
tissue	turnover	and	attenuation	of	 IL6	signaling,	metabolic	effects	
related to dysregulation of other cytokines (Bidault et al., 2020; 
Griveau	et	al.,	2020;	Liu	et	al.,	2019)	might	suddenly	establish	a	fatal	
condition.	Optimization	of	tocilizumab	dosage	and	combination	with	
drugs or molecular approaches already explored for HGPS treat-
ment may pave the way to effective therapeutic strategies (Cenni 
et	al.,	2020;	Liu	et	al.,	2019).	For	 instance,	 tocilizumab	could	elicit	
a synergistic effect with lonafarnib, the farnesyltransferase inhib-
itor used in the ongoing HGPS clinical trial (https://www.clini caltr 
ials.gov/ct2/show/NCT00	425607).	 Of	 note,	 lonafarnib	 has	 been	
reported to lower progerin levels in HGPS iPSCs-derived smooth 
muscle cells subjected to biomechanical strain (Ribas et al., 2017). 
Also, combination with statins, shown to improve HGPS cellular phe-
notype	(Columbaro	et	al.,	2005)	and	reduce	IL6	levels	(Ribas	et	al.,	
2017), warrants investigation.
Finally, our study indicates that tocilizumab could be explored 
in aging-associated disorders, including sarcopenia, cachexia, and 
motor impairment and more in general to mitigate the detrimental 
effects of age-related inflammation that impinge upon the onset of 
dysfunctions and disability at late ages and on the overall quality of 
life in the elderly.
4  |  MATERIAL S AND METHODS
4.1  |  IL6 detection and neutralization





Tecan)	 was	 used	 to	 measure	 IL6	 signal.	 For	 IL6	 neutralization	 in	
HGPS fibroblast cultures, 100 µg/ml of neutralizing antibody was 
added to culture medium for 72 h. Tocilizumab was administered to 
LmnaG609G/G609G or LmnaG609G/+ by intraperitoneal injection every 
three	days	starting	at	weaning	(typically	at	post-natal	week	4)	and	
continued up to the humane endpoint, when the animals were euth-
anized.	A	dosage	of	40	mg/kg	(body	weight)	per	week	was	estimated	
the most efficient. Saline solution was injected in parallel to animals 
to be used as controls.
4.2  |  Mice
All animal studies were performed in accordance with EU regula-
tions,	the	guidelines	of	the	Italian	Ministry	of	Health	and	the	local	
committee for animal welfare. Experiments were also in compli-
ance with ethical rules and the experimental protocol was ap-
proved	by	the	Italian	Ministry	of	Health	(No.	653/2016-PR	issued	on	
07/04/2016	and	update	No.	AC750.13-1105).	Homozygous	or	het-
erozygous mice (C57BL/6 strain) carrying the mouse Lmna	G609G	
mutation, equivalent to LMNA G608G mutation of human HGPS, 
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were	kindly	provided	by	Prof.	Carlos	Lopez-Otin	(Oviedo	University,	
Spain)	(Osorio	et	al.,	2012).
Phenotype and molecular features of LmnaG609G/G609G and 
LmnaG609G/+ progeroid mice have been characterized and previously 
reported	(Osorio	et	al.,	2011;	Zaghini	et	al.,	2020).	Co-housed	wild-
type littermates (Lmna+/+) were used as controls. Two to five mice 
were housed in each cage, at a constant temperature of 22 ± 1°C 
under a 12-hour light/12-hour dark cycle with free access to food and 
water. Animals were randomly assigned to each group. Analyses of 
phenotypes of mice were performed at different times throughout 
their lifespan, and at time of death. Procedures performed in mice 
include: weight monitoring), performance tests to assess locomotor 
activity (open field test), micro-computed tomography (microCT) 
analysis of femurs with a microCT scan and tissue collection. As a 
whole, 10 Lmna+/+male mice and 10 females, 22 LmnaG609G/+ males 
and 20 females and 13 LmnaG609G/G609G males and 7 females were 
used in this study.
To assess motor activity, a subset of mice (3 mice per geno-
type,	all	males)	underwent	the	open	field	test	at	85,	95,	105	and	
110 days of age. A semi-transparent plastic white rectangular box 
(70 cm × 50 cm), was used as arena (Zaghini et al., 2020). At the 
beginning of the test, each mouse was set in the middle of the 
arena. Experienced operators during a 30 min period observed 
and recorded and evaluated: travelled quadrants, time spent mov-
ing, time spent in the central area, and vertical movements. The 
room was isolated from sound, and unintentional interruptions 
were avoided.
4.3  |  Skeletal microCT
Mouse	femurs	 immersed	 in	saline	solution	within	a	plastic	holder	
were analyzed on a microCT model Skyscan 1072 (Bruker Corp., 
MicroCT	unit).	The	scanning	parameters	were	set	at	a	voxel	reso-
lution of 10.78 µm, 50 kV, 200 µA, 1 mm aluminum filter, expo-
sure	 time	 5936	 ms,	 image	 averaged	 on	 2	 frames,	 rotation	 180°	
and	a	rotation	step	of	0.9°.	Tomographic	image	reconstruction	was	
based	on	NRecon	software	(Bruker	Corp.,	MicroCT	unit).	A	global	
threshold was applied to select bone tissue (gray threshold value 
117/255).	Mouse	femur	and	trabecular	bone	were	also	qualitatively	
analyzed on 3D reconstructions thanks to CT-Vox software (Bruker 
Corp.,	MicroCT	unit)	to	identify	any	possible	alteration.	Trabecular	
and cortical morphology of the femur were investigated by use 
of	 CT-Analyzer	 software	 (Bruker	 Corp.,	MicroCT	 unit).Trabecular	
bone was measured on the following parameters: bone volume 
fraction (bone volume/total volume or BV/TV, %), trabecular bone 
thickness (TbTh, mm), trabecular separation (TbSp, mm), and tra-
becular	bone	number	(TbN,	1/mm).	Volume	of	interest	for	trabecu-
lar tissue was selected with the anatomical reference of the distal 
growth plate, starting about 0.215 mm proximally from the growth 
plate level (offset of 50 image slices), and extending in the direction 
of	the	femoral	head	for	about	1.72	mm	(height	of	450	image	slices.	
This section of the diaphysis is defined in coincidence to the length 
investigated by mechanical testing. The femur biomechanical 
length was defined as the longitudinal distance between the cra-
nial side of the intertrochanteric fossa and the intercondylar fossa.
4.4  |  Cell cultures and transfection
All	human	cell	cultures	used	in	this	study	were	from	BioLaM	biobank	
(Rizzoli	 Orthopedic	 Institute	 Ethical	 Committee	 approval	 no.	
0018250–2016, in compliance with all local and EU ethical rules). 
Control and HGPS fibroblast cultures had been obtained from skin 
biopsies	as	previously	described	(Columbaro	et	al.,	2005).	Necropsy	
of Lmna+/+, LmnaG609G/G609G, and LmnaG609G/+progeroid mice was 
performed according to local and EU ethical rules. Cells were cul-
tured	in	high-glucose	Dulbecco's	modified	Eagle's	medium	(DMEM)	
(D5648;	 Sigma)	 supplemented	with	 20%	 fetal	 bovine	 serum	 (FBS)	
(10270-106;	 Thermo	 Fisher),	 100	 IU/ml	 penicillin	 and	 100	 µg/ml	
streptomycin	(15140122;	Thermo	Fisher)	(growth	medium)	in	a	5%	
CO2 humidified atmosphere at 37°C.
Adipocyte, osteoblast, tenocyte and myoblast cultures were 
established as previously described from mouse subcutaneous fat, 
rib bone and skeletal muscle (vastus lateralis), respectively, and 
differentiated according to established protocols (Antoniel et al., 
2020;	 Avnet	 et	 al.,	 2011;	 Mattioli	 et	 al.,	 2011;	 Pellegrini	 et	 al.,	
2019).
Differentiation of cultured mouse pre-adipocytes was as-
sessed	by	Oil	Red	O	staining.	Cells	were	washed	twice	with	PBS	
and fixed with 10% Formalin Solution (HT501128, Fisher) in dis-
tilled	water	for	45	min.	After	a	5	min	incubation	with	60%	isopro-
panol,	Oil	Red	working	 solution	was	added	 to	 the	 fixed	cells	 for	
5	min	at	room	temperature.	Images	were	obtained	by	using	a	Zeiss	
Axio A1 inverted microscope equipped with a digital camera and 
ZEN	software.
Mineralized	 matrix	 formation	 in	 osteoblast	 cultures	 was	 de-
tected by alizarin red S (ARS) staining. Cells were washed twice with 
PBS and fixed with 10% Formalin Solution in disttilled water for 
5 min, washed twice with distilled water and stained with ARS work-
ing solution for 5 min. Samples were observed using a Zeiss Axio A1 
inverted microscope equipped with a digital camera. Pictures were 
taken	using	ZEN	software.
To measure nuclear circularity, the contour ratio algorithm was 
used and calculated by following the formula:
HEK293	 cells	 were	 transiently	 transfected	 with	 plasmids	 ex-
pressing wild-type prelamin A (LA-WT), which undergoes nor-
mal maturation, progerin (LA-Δ50), which cannot be processed by 
ZMPSTE24	 endoprotease,	 or	 R527H-mutated	 lamin	 A,	 associated	
with	MADA	 (Lattanzi	 et	 al.,	 2007).	 Transfections	were	 performed	
using	 lipofectamine-2000	 (18324012;	 Invitrogen)	 according	 to	 the	
manufacturer's instructions. After transfection, cells were incubated 
for	48	h,	if	not	differently	stated.
contour ratio = 4 × nucleararea∕nuclearperimeter2
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4.5  |  Biochemical analysis
Cells	were	fixed	in	4%	paraformaldehyde,	post-fixed	using	absolute	
methanol for 5 min, and stained according to previously published 
protocols	 (Mattioli	 et	 al.,	 2011).	 Primary	 antibodies	 were	 applied	
overnight	at	4°C,	and	secondary	antibodies	were	used	for	1	hour	at	
room	temperature.	Nuclei	were	counterstained	with	4,6-diamidino-
2-phenylindole	 (DAPI).	 Sample	 observation	 and	 image	 acquisition	
were	 performed	 using	 a	 Nikon	 Eclipse	 Ni	 epifluorescence	 micro-
scope	equipped	with	a	digital	CCD	camera	and	NIS-	Elements	4.3	
AR software. Photoshop CS and Photoshop 7 were used for image 
processing.	Mean	fluorescence	intensity	(MFI)	was	measured	using	
NIS-	Elements	4.3	AR.
For Western blot analysis, tissues and cells were lysed in buffer 
containing:	20	mM	Tris-HCl	 (pH	=	7.5),	1%	SDS,	1	mM	Na3VO4,	
1	mM	PMSF,	5%	beta-mercaptoethanol,	 and	protease	 inhibitors.	
Proteins were subjected to SDS gradient gel (5%–20%) electropho-
resis	and	transferred	to	nitrocellulose	membrane	overnight	at	4°C.	
After incubation with primary and secondary antibodies, immuno-
blotted	bands	were	revealed	by	Invitrogen	ECL	detection	system.	
Densitometry was performed by a Bio-Rad GS800 Densitometer 
equipped	 with	 Quantity	 One	 Software.	 Densitometric	 values	
were normalized to corresponding GAPDH bands if not differently 
stated.
4.6  |  Histology
Skeletal muscle or myocardium fragments from Lmna+/+ or 
LmnaG609G/G609Gmice were frozen in melting isopentane and stored 
in liquid nitrogen. Unfixed cryosections were subjected to immuno-
fluorescence staining as detailed above.
Samples of aortic arch promptly after necropsy were fixed with 
formalin and embedded in paraffin. Histology was based on hema-
toxylin–eosin,	PAS	 stain	 (Bio	Optica,	Milan,	 Italy;	P.A.S.	Hotchkiss	
–	MC	Manus,	 04-130802)	 and	Alcian	 stains	 at	 pH	 2,5	 and	 1	 (Bio	
Optica;	Alcian	Blu,	04-160802).	Reduction	of	cellularity	in	aorta	mid-
dle coat was graded as described (Zaghini et al., 2020) and reported 
in Table S1. For aorta examination, three photographs per sample 
were	acquired	with	a	DFK	33UX264	camera	coupled	with	a	Leica	
TM	DMLB	microscope	(TIFF	format	2448	×	2048,	Obj	20×).
The area was manually delineated (lowest selected 
area	=	40,000	µm2),	and	leiomyocytes	were	manually	counted	with	ImageJ	
software (https://imagej.nih.gov/ij/index.html/). Finally, cellularity was 
assessed and expressed as the number of leiomyocytes/10,000 µm2.
4.7  |  Antibodies
Antibodies employed in this study were as follows: anti-STAT3 
phosphorylated on tyrosine 705 (P-STAT3 Y705), anti-STAT3 phos-
phorylated on Serine 727 (P-STAT3 S727), and anti-STAT3 from 
Thermo Fisher Scientific; anti-γ-H2AX,	 rabbit	 polyclonal	 (4937;	
Cell	Signaling);	anti-p21,	rabbit	polyclonal	(MA5-14949;	Invitrogen);	
anti-Emerin,	 mouse	 monoclonal	 (MONX10804;	 Monosan);	 anti-
β-tubulin; anti-lamin A/C, goat polyclonal (SC-6215; Santa Cruz 




4.8  |  Transmission Electron Microscopy
Tissue fragments (tendon, skeletal muscle and adipose tissue) were 
fixed	with	2.5%	glutaraldehyde	in	0.1	M	cacodylate	buffer,	pH	7.3.	
Semithin sections were stained with toluidine blue for preliminary 
optical microscopy sample observation. Ultrathin sections were 
treated for transmission electron microscopy observation as de-
scribed (Filesi et al., 2005). After post-fixation with 1% osmium 
tetroxide	 in	 0.1	M	 cacodylate	 buffer	 for	 1hour,	 samples	were	 de-
hydrated in an ethanol series, infiltrated with propylene oxide, and 
embedded in Epon812 epoxy resin following standard procedures. 
Ultrathin sections (60 nm thick) were stained with uranyl acetate 
and	lead	citrate	and	observed	at	a	0°	tilt	angle	with	a	JEOL	JEM-1011	
transmission electron microscope operated at 100 kV.
4.9  |  Luciferase assays
One	 day	 before	 transfection,	 human	 control	 or	HGPS	 fibroblasts	
were seeded on 6-well plates and transfected with 500 ng of lu-
ciferase	 reporters	 driven	 by	 the	 −2,161	 to	 −41	 bp	 IL6	 promoter	
fragment	 (kindly	 provided	 by	W.	 L.	 Farrar,	 NCI-Frederick	 Cancer	
Research and Development Center, USA, Papi et al., 2012). Firefly 
Luciferase was normalized by co-transfecting 10 ng of Thymidine 
Kinase Renilla Luciferase reporter (Promega Corporation). All lucif-
erase assays were performed in triplicate following manufacturer's 
instructions (Promega).
4.10  |  Real-time PCR
Total	 RNA	 was	 extracted	 using	 the	 TRI	 Reagent	 Solution	
(Invitrogen)	and	 treated	with	TURBO	DNase	 (Invitrogen).	 cDNAs	
were	 produced	 using	 the	 High-Capacity	 RNA-to-cDNA	 Kit	
(Applied Biosystems) according to the manufacture's protocol. 
Gene expression was determined by qPCR and Power SYBR Green 
PCR master mix (Applied Biosystems). Expression analysis was 
performed	 using	 the	 Applied	 Biosystem	 7900HT	 real-time	 PCR	
system. Fold change of expression levels was analyzed by the 
∆∆CT	method,	and	transcript	levels	were	normalized	by	using	the	
housekeeping reference gene GAPDH. The qPCR primer list is re-
ported in Table S2.
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4.11  |  Statistical analysis
Statistical analysis was performed with GraphPad Prism version 7 
(Prism). Data were expressed as means ± standard error of the mean 
(SEM), as indicated in the figure legends, and tested using one-way 
ANOVA	(for	multiple	comparisons)	or	two-tailed	Student's	t test (two 
groups).	For	the	comparison	of	different	groups	in	Kaplan–Meier	sur-
vival	plots,	we	used	a	log-rank	(Mantel-Cox)	test.	p	values	of	≤0.05	are	
considered statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001, 
****p	<	0.0001;	Non-significant	(NS),	p	≥	0.05.
ACKNOWLEDG EMENTS
The authors thank patients and families for donating cell cultures; 
the	Italian	Network	for	Laminopathies	for	sharing	discussion	on	this	
work;	Prof.	Carlos	Lopez-Otin	for	the	kind	gift	of	LmnaG609G/+ mice; 
Despina Kiriakidu and Aurelio Valmori for technical assistance.






GL involved in funding acquisition. AZ and GL contributed to resources.
DATA AVAIL ABILIT Y S TATEMENT
The data that support the findings of this study are available from 
the corresponding author upon reasonable request.
ORCID
Giovanna Lattanzi  https://orcid.org/0000-0002-7103-8722 
R E FE R E N C E S




types of Hutchinson-Gilford Progeria Syndrome. Nature Communications, 
10(1),	4990.	https://doi.org/10.1038/s4146	7-019-13018	-3
Antoniel,	M.,	Traina,	F.,	Merlini,	L.,	Andrenacci,	D.,	Tigani,	D.,	Santi,	S.,	Cenni,	V.,	
Sabatelli, P., Faldini, C., & Squarzoni, S. (2020). Tendon extracellular ma-
trix remodeling and defective cell polarization in the presence of colla-
gen	VI	mutations.	Cells, 9(2),	409.	https://doi.org/10.3390/cells	9020409
Araujo-Vilar,	D.,	&	Santini,	F.	(2019).	Diagnosis	and	treatment	of	lipodystro-
phy: A step-by-step approach. Journal of Endocrinological Investigation, 
42(1),	61–73.	https://doi.org/10.1007/s4061	8-018-0887-z
Avnet,	 S.,	 Pallotta,	 R.,	 Perut,	 F.,	 Baldini,	N.,	 Pittis,	M.	G.,	 Saponari,	A.,	
Lucarelli,	 E.,	 Dozza,	 B.,	 Greggi,	 T.,	 Maraldi,	 N.	 M.,	 Capanni,	 C.,	
Mattioli,	 E.,	 Columbaro,	 M.,	 &	 Lattanzi,	 G.	 (2011).	 Osteoblasts	
from a mandibuloacral dysplasia patient induce human blood 
precursors to differentiate into active osteoclasts. Biochimica 




of	 interleukin	 (IL)-6,	 IL-6.soluble	 IL-6	 receptor	 (sIL-6R),	 and	 IL-6.
sIL-6R.sgp130	complexes	allows	simultaneous	classic	and	trans-sig-
naling. Journal of Biological Chemistry, 293(18), 6762–6775. https://
doi.org/10.1074/jbc.RA117.001163
Bean,	C.,	Verma,	N.	K.,	Yamamoto,	D.	L.,	Chemello,	F.,	Cenni,	V.,	Filomena,	
M.	 C.,	 &	 Lanfranchi,	 G.	 (2014).	 Ankrd2	 is	 a	 modulator	 of	 NF-
kappaB-mediated inflammatory responses during muscle differ-
entiation. Cell Death & Disease, 5, e1002. https://doi.org/10.1038/
cddis.2013.525
Bidault,	 G.,	 Garcia,	 M.,	 Capeau,	 J.,	 Morichon,	 R.,	 Vigouroux,	 C.,	 &	
Bereziat,	V.	(2020).	Oxidative	stress	and	senescence	in	human	cor-




Emerin-prelamin A interplay in human fibroblasts. Biology of the 
Cell, 101(9),	541–554.	https://doi.org/10.1042/BC200	80175
Capanni,	 C.,	 Del	 Coco,	 R.,	 Squarzoni,	 S.,	 Columbaro,	 M.,	 Mattioli,	 E.,	
Camozzi,	 D.,	 Rocchi,	 A.,	 Scotlandi,	 K.,	 Maraldi,	 N.,	 &	 Foisner,	 R.	
(2008). Prelamin A is involved in early steps of muscle differenti-
ation. Experimental Cell Research, 314(20), 3628–3637. https://doi.
org/10.1016/j.yexcr.2008.09.026
Cenni,	V.,	Capanni,	C.,	Mattioli,	E.,	Schena,	E.,	Squarzoni,	S.,	Bacalini,	M.	
G., Garagnani, P., Salvioli, S., Franceschi, C., & Lattanzi, G. (2020). 
Lamin A involvement in ageing processes. Ageing Research Reviews, 
62, 101073. https://doi.org/10.1016/j.arr.2020.101073
Cenni,	 V.,	 D'Apice,	 M.	 R.,	 Garagnani,	 P.,	 Columbaro,	 M.,	 Novelli,	 G.,	
Franceschi,	 C.,	 &	 Lattanzi,	 G.	 (2018).	 Mandibuloacral	 dysplasia:	
A premature ageing disease with aspects of physiological age-
ing. Ageing Research Reviews, 42, 1–13. https://doi.org/10.1016/j.
arr.2017.12.001
Cenni,	V.,	Kojic,	S.,	Capanni,	C.,	Faulkner,	G.,	&	Lattanzi,	G.	(2019).	Ankrd2	
in mechanotransduction and oxidative stress response in skeletal 
muscle:	New	cues	for	the	pathogenesis	of	muscular	laminopathies.	
Oxidative Medicine and Cellular Longevity, 2019,	 7318796.	 https://
doi.org/10.1155/2019/7318796
Columbaro,	 M.,	 Capanni,	 C.,	 Mattioli,	 E.,	 Novelli,	 G.,	 Parnaik,	 V.	 K.,	
Squarzoni,	S.,	Maraldi,	N.	M.,	&	Lattanzi,	G.	(2005).	Rescue	of	het-
erochromatin organization in Hutchinson-Gilford progeria by drug 
treatment. Cellular and Molecular Life Sciences, 62(22),	2669–2678.	
https://doi.org/10.1007/s0001 8-005-5318-6
De	 Sandre-Giovannoli,	 A.,	 Bernard,	 R.,	 Cau,	 P.,	 Navarro,	 C.,	 Amiel,	 J.,	
Boccaccio,	I.,	&	Levy,	N.	(2003).	Lamin	a	truncation	in	Hutchinson-
Gilford progeria. Science, 300(5628), 2055. https://doi.org/10.1126/
scien	ce.1084125
del	Campo,	L.,	Sánchez-López,	A.,	Salaices,	M.,	von	Kleeck,	R.	A.,	Expósito,	
E.,	 González-Gómez,	 C.,	 Cussó,	 L.,	 Guzmán-Martínez,	 G.,	 Ruiz-
Cabello,	 J.,	 Desco,	M.,	Assoian,	 R.	 K.,	 Briones,	A.	M.,	 &	Andrés,	V.	
(2019).	Vascular	smooth	muscle	cell-specific	progerin	expression	in	a	
mouse model of Hutchinson-Gilford progeria syndrome promotes ar-
terial stiffness: Therapeutic effect of dietary nitrite. Aging Cell, 18(3), 
e12936.	https://doi.org/10.1111/acel.12936
Emery, P., Rondon, J., Parrino, J., Lin, Y., Pena-Rossi, C., van Hoogstraten, 
H.,	Graham,	N.	M.	H.,	 Liu,	N.,	 Paccaly,	A.,	Wu,	R.,	&	 Spindler,	A.	
(2019).	 Safety	 and	 tolerability	 of	 subcutaneous	 sarilumab	 and	
intravenous tocilizumab in patients with rheumatoid arthritis. 





Collins, F. S. (2003). Recurrent de novo point mutations in lamin 
A cause Hutchinson-Gilford progeria syndrome. Nature, 423(6937),	
293–298.	https://doi.org/10.1038/natur	e01629
Fang,	 L.,	 Choudhary,	 S.,	 Zhao,	 Y.,	 Edeh,	 C.	 B.,	 Yang,	 C.,	 Boldogh,	 I.,	 &	
Brasier,	 A.	 R.	 (2014).	 ATM	 regulates	 NF-kappaB-dependent	 im-
mediate-early genes via RelA Ser 276 phosphorylation coupled to 
16 of 17  |     SQUARZONI et Al.





and chromatin organization in mandibuloacral dysplasia, a rare form 
of laminopathy. Physiological Genomics, 23(2), 150–158.
Filgueiras-Rama, D., Rivera Torres, J., & Andres, V. (2018). 
Electrocardiographic abnormalities in patients with Hutchinson-
Gilford Progeria Syndrome. JAMA Cardiology, 3(10),	 1024–1025.	
https://doi.org/10.1001/jamac ardio.2018.2100
Gargiuli,	 C.,	 Schena,	 E.,	 Mattioli,	 E.,	 Columbaro,	 M.,	 D'Apice,	 M.	 R.,	
Novelli,	G.,	Greggi,	T.,	&	Lattanzi,	G.	(2018).	Lamins	and	bone	dis-
orders: Current understanding and perspectives. Oncotarget, 9(32), 




Gonzalo, S., Kreienkamp, R., & Askjaer, P. (2017). Hutchinson-Gilford 
Progeria	 Syndrome:	A	premature	 aging	disease	 caused	by	 LMNA	







itors Lonafarnib, Pravastatin, and Zoledronic Acid in children with 
Hutchinson-Gilford Progeria Syndrome. Circulation, 134(2),	 114–
125.	https://doi.org/10.1161/CIRCU	LATIO	NAHA.116.022188
Gordon,	 L.	 B.,	 Shappell,	 H.,	 Massaro,	 J.,	 D'Agostino,	 R.	 B.,	 Brazier,	 J.,	
Campbell,	S.	E.,	Kleinman,	M.	E.,	&	Kieran,	M.	W.	(2018).	Association	
of Lonafarnib treatment vs no treatment with mortality rate in pa-
tients with Hutchinson-Gilford Progeria Syndrome. JAMA, 319(16), 
1687–1695.	https://doi.org/10.1001/jama.2018.3264
Griveau,	A.,	Wiel,	C.,	Ziegler,	D.	V.,	Bergo,	M.	O.,	&	Bernard,	D.	(2020).	The	
JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes. 
Aging Cell, 19(4),	e13122.	https://doi.org/10.1111/acel.13122
Hamczyk,	 M.	 R.,	 &	 Andres,	 V.	 (2019).	 Vascular	 smooth	 muscle	 cell	
loss underpins the accelerated atherosclerosis in Hutchinson-
Gilford progeria syndrome. Nucleus, 10(1),	 28–34.	 https://doi.
org/10.1080/19491	034.2019.1589359
Hamczyk,	M.	R.,	 del	Campo,	 L.,	&	Andres,	V.	 (2018).	Aging	 in	 the	 car-
diovascular system: Lessons from Hutchinson-Gilford Progeria 
Syndrome. Annual Review of Physiology, 80,	 27–48.	 https://doi.
org/10.1146/annur	ev-physi	ol-02131	7-121454
Hamczyk,	 M.	 R.,	 Villa-Bellosta,	 R.,	 Gonzalo,	 P.,	 Andrés-Manzano,	 M.	
J.,	Nogales,	P.,	Bentzon,	J.	F.,	López-Otín,	C.,	&	Andrés,	V.	 (2018).	
Vascular smooth muscle-specific progerin expression accelerates 
atherosclerosis and death in a mouse model of Hutchinson-Gilford 
Progeria Syndrome. Circulation, 138(3), 266–282. https://doi.
org/10.1161/CIRCU	LATIO	NAHA.117.030856
Kamiya,	N.,	Kuroyanagi,	G.,	Aruwajoye,	O.,	&	Kim,	H.	K.	W.	(2019).	 IL6	
receptor blockade preserves articular cartilage and increases 
bone volume following ischemic osteonecrosis in immature mice. 
Osteoarthritis Cartilage, 27(2), 326–335. https://doi.org/10.1016/j.
joca.2018.10.010
Kreienkamp, R., Billon, C., Bedia-Diaz, G., Albert, C. J., Toth, Z., Butler, 
A.	 A.,	McBride-Gagyi,	 S.,	 Ford,	 D.	 A.,	 Baldan,	 A.,	 Burris,	 T.	 P.,	 &	
Gonzalo,	 S.	 (2019).	Doubled	 lifespan	 and	 patient-like	 pathologies	
in progeria mice fed high-fat diet. Aging Cell, 18(1), e12852. https://
doi.org/10.1111/acel.12852
Kreienkamp,	R.,	Croke,	M.,	Neumann,	M.	A.,	Bedia-Diaz,	G.,	Graziano,	S.,	
Dusso, A., Dorsett, D., Carlberg, C., & Gonzalo, S. (2016). Vitamin D 
receptor signaling improves Hutchinson-Gilford progeria syndrome 
cellular phenotypes. Oncotarget, 7(21), 30018–30031. https://doi.
org/10.18632/	oncot	arget.9065
Kreienkamp,	 R.,	 &	 Gonzalo,	 S.	 (2020).	 Metabolic	 dysfunction	 in	




S. (2018). A cell-intrinsic interferon-like response links replication 
stress to cellular aging caused by progerin. Cell Reports, 22(8), 
2006–2015.	https://doi.org/10.1016/j.celrep.2018.01.090
Larrieu, D., Vire, E., Robson, S., Breusegem, S. Y., Kouzarides, T., & 
Jackson,	S.	P.	(2018).	Inhibition	of	the	acetyltransferase	NAT10	nor-
malizes progeric and aging cells by rebalancing the Transportin-1 




Foisner, R., & Capanni, C. (2007). Pre-Lamin A processing is linked 
to heterochromatin organization. Journal of Cellular Biochemistry, 
102(5),	1149–1159.	https://doi.org/10.1002/jcb.21467
Lattanzi,	 G.,	 Ortolani,	 M.,	 Columbaro,	 M.,	 Prencipe,	 S.,	 Mattioli,	 E.,	
Lanzarini,	 C.,	Maraldi,	N.	M.,	 Cenni,	 V.,	Garagnani,	 P.,	 Salvioli,	 S.,	
Storci,	G.,	Bonafe,	M.,	Capanni,	C.,	&	Franceschi,	C.	(2014).	Lamins	
are rapamycin targets that impact human longevity: a study in cen-
tenarians. Journal of Cell Science, 127(Pt	 1),	 147–157.	 https://doi.
org/10.1242/jcs.133983
Levy,	 Y.,	 Ross,	 J.	 A.,	 Niglas,	 M.,	 Snetkov,	 V.	 A.,	 Lynham,	 S.,	 Liao,	 C.-
Y.,	 Puckelwartz,	 M.	 J.,	 Hsu,	 Y.-M.,	 McNally,	 E.	 M.,	 Alsheimer,	
M.,	 Harridge,	 S.	 D.	 R.,	 Young,	 S.	 G.,	 Fong,	 L.	 G.,	 Español,	 Y.,	
Lopez-Otin,	C.,	 Kennedy,	B.	K.,	 Lowe,	D.	A.,	&	Ochala,	 J.	 (2018).	
Prelamin A causes aberrant myonuclear arrangement and results 
in muscle fiber weakness. JCI Insight, 3(19),	 e120920.	https://doi.
org/10.1172/jci.insig	ht.120920
Liu,	C.,	Arnold,	R.,	Henriques,	G.,	&	Djabali,	K.	(2019).	Inhibition	of	JAK-
STAT signaling with baricitinib reduces inflammation and improves 
cellular homeostasis in progeria cells. Cells, 8(10), 1276. https://doi.
org/10.3390/cells	8101276
Liu,	Y.,	Drozdov,	 I.,	Shroff,	R.,	Beltran,	L.	E.,	&	Shanahan,	C.	M.	 (2013).	
Prelamin A accelerates vascular calcification via activation of the 
DNA	damage	response	and	senescence-associated	secretory	phe-
notype in vascular smooth muscle cells. Circulation Research, 112(10), 
99–109.	https://doi.org/10.1161/CIRCR	ESAHA.111.300543
Mallalieu,	 N.	 L.,	 Wimalasundera,	 S.,	 Hsu,	 J.	 C.,	 Douglass,	 W.,	 Wells,	
C.,	 Penades,	 I.	 C.,	 Cuttica,	 R.,	 Huppertz,	 H.-I.,	 Joos,	 R.,	 Kimura,	
Y.,	 Milojevic,	 D.,	 Rosenkranz,	 M.,	 Schikler,	 K.,	 Constantin,	 T.,	 &	
Wouters,	C.	 (2019).	 Intravenous	dosing	of	 tocilizumab	 in	patients	
younger than two years of age with systemic juvenile idiopathic 
arthritis: results from an open-label phase 1 clinical trial. Pediatric 
Rheumatology Online Journal, 17(1), 57. https://doi.org/10.1186/
s1296	9-019-0364-z
Mattioli,	 E.,	 Andrenacci,	 D.,	 Garofalo,	 C.,	 Prencipe,	 S.,	 Scotlandi,	 K.,	
Remondini, D., & Lattanzi, G. (2018). Altered modulation of lamin 
A/C-HDAC2 interaction and p21 expression during oxidative 
stress response in HGPS. Aging Cell, 17(5),	 e12824.	 https://doi.
org/10.1111/acel.12824
Mattioli,	 E.,	 Columbaro,	 M.,	 Capanni,	 C.,	 Maraldi,	 N.	 M.,	 Cenni,	 V.,	
Scotlandi,	K.,	Marino,	M.	T.,	Merlini,	L.,	Squarzoni,	S.,	&	Lattanzi,	G.	
(2011).	Prelamin	A-mediated	 recruitment	of	SUN1	 to	 the	nuclear	
envelope directs nuclear positioning in human muscle. Cell Death 
and Differentiation, 18(8), 1305–1315. https://doi.org/10.1038/
cdd.2010.183
Mihara,	M.,	Ohsugi,	Y.,	&	Kishimoto,	T.	(2011).	Tocilizumab,	a	humanized	
anti-interleukin-6 receptor antibody, for treatment of rheumatoid 
arthritis. Open Access Rheumatology: Research and Reviews, 3,	19–
29.	https://doi.org/10.2147/OARRR.S17118
    |  17 of 17SQUARZONI et Al.
Osmanagic-Myers,	 S.,	 Kiss,	A.,	Manakanatas,	 C.,	 Hamza,	O.,	 Sedlmayer,	 F.,	
Szabo,	P.	 L.,	Fischer,	 I.,	 Fichtinger,	P.,	Podesser,	B.	K.,	Eriksson,	M.,	&	
Foisner,	R.	(2019).	Endothelial	progerin	expression	causes	cardiovascu-
lar pathology through an impaired mechanoresponse. Journal of Clinical 
Investigation, 129(2),	531–545.	https://doi.org/10.1172/JCI12	1297
Osorio,	F.	G.,	Barcena,	C.,	Soria-Valles,	C.,	Ramsay,	A.	 J.,	de	Carlos,	F.,	
Cobo,	 J.,	 &	 Lopez-Otin,	 C.	 (2012).	 Nuclear	 lamina	 defects	 cause	
ATM-dependent	NF-kappaB	activation	and	 link	accelerated	aging	
to a systemic inflammatory response. Genes & Development, 26(20), 
2311–2324.	https://doi.org/10.1101/gad.197954.112
Osorio,	F.	G.,	Navarro,	C.	L.,	Cadinanos,	J.,	Lopez-Mejia,	 I.	C.,	Quiros,	P.	M.,	
Bartoli,	 C.,	 Rivera,	 J.,	 Tazi,	 J.,	 Guzman,	 G.,	 Varela,	 I.,	 Depetris,	 D.,	 de	
Carlos,	 F.,	Cobo,	J.,	Andres,	V.,	De	Sandre-Giovannoli,	A.,	 Freije,	J.	M.	
P.,	Levy,	N.,	&	Lopez-Otin,	C.	(2011).	Splicing-directed	therapy	in	a	new	





inflammation dependent survival of breast cancer stem cells. Cell Death 
Differ, 9(7),	1208–1219.	https://doi.org/10.1038/cdd.2011.207
Pellegrini,	 C.,	 Columbaro,	M.,	 Capanni,	 C.,	 D'Apice,	M.	 R.,	 Cavallo,	 C.,	
Murdocca,	M.,	 Lattanzi,	G.,	&	Squarzoni,	 S.	 (2015).	All-trans	 reti-
noic acid and rapamycin normalize Hutchinson Gilford progeria fi-
broblast phenotype. Oncotarget, 6(30),	29914–29928.	https://doi.
org/10.18632/	oncot	arget.4939
Pellegrini,	 C.,	 Columbaro,	M.,	 Schena,	 E.,	 Prencipe,	 S.,	 Andrenacci,	D.,	
Iozzo,	 P.,	 Angela	 Guzzardi,	 M.,	 Capanni,	 C.,	 Mattioli,	 E.,	 Loi,	 M.,	
Araujo-Vilar,	D.,	 Squarzoni,	 S.,	Cinti,	 S.,	Morselli,	 P.,	Giorgetti,	A.,	
Zanotti,	 L.,	 Gambineri,	 A.,	 &	 Lattanzi,	 G.	 (2019).	 Altered	 adipo-
cyte differentiation and unbalanced autophagy in type 2 Familial 
Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue 
browning. Experimental & Molecular Medicine, 51(8), 1–17. https://
doi.org/10.1038/s1227	6-019-0289-0
Ragnauth,	 C.	 D.,	Warren,	 D.	 T.,	 Liu,	 Y.,	McNair,	 R.,	 Tajsic,	 T.,	 Figg,	 N.,	
Shroff,	R.,	Skepper,	J.,	&	Shanahan,	C.	M.	(2010).	Prelamin	A	acts	to	
accelerate smooth muscle cell senescence and is a novel biomarker 




Biomechanical strain exacerbates inflammation on a progeria-on-a-
Chip	Model.	 Small (Weinheim an Der Bergstrasse, Germany), 13(15), 
1603737. https://doi.org/10.1002/smll.20160 3737
Rodier,	F.,	Coppé,	J.-P.,	Patil,	C.	K.,	Hoeijmakers,	W.	A.	M.,	Muñoz,	D.	P.,	
Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. 
(2009).	Persistent	DNA	damage	signalling	triggers	senescence-as-




Schramm, A., & Bijlsma, J. W. J. (2020). Effect on efficacy and safety 
trial outcomes of also enrolling patients on ongoing glucocorticoid 
therapy in rheumatoid arthritis clinical trials of tocilizumab or adalim-
umab or methotrexate monotherapy. Annals of the Rheumatic Diseases, 
79(4),	460–463.	https://doi.org/10.1136/annrh	eumdi	s-2019-216537
Scaffidi,	 P.,	 &	Misteli,	 T.	 (2008).	 Lamin	 A-dependent	 misregulation	 of	
adult stem cells associated with accelerated ageing. Nature Cell 
Biology, 10(4),	452–459.	https://doi.org/10.1038/ncb1708
Squarzoni, S., Sabatelli, P., Capanni, C., Lattanzi, G., Rutigliano, C., 
Columbaro,	 M.,	 &	Maraldi,	 N.	 M.	 (2005).	 Emerin	 increase	 in	 re-











the Hutchinson-Gilford progeria syndrome mutation results in a re-
versible bone phenotype, whereas resveratrol treatment does not 
show overall beneficial effects. FASEB Journal, 29(8),	3193–3205.	
https://doi.org/10.1096/fj.14-269217
Sun,	 S.,	Qin,	W.,	Tang,	 X.,	Meng,	Y.,	Hu,	W.,	 Zhang,	 S.,	&	 Liu,	 B.	 (2020).	
Vascular endothelium-targeted Sirt7 gene therapy rejuvenates blood 
vessels and extends life span in a Hutchinson-Gilford progeria model. 
Science Advances, 6(8), eaay5556. https://doi.org/10.1126/sciadv.
aay5556
Vidal, C., Bermeo, S., Fatkin, D., & Duque, G. (2012). Role of the nuclear en-
velope in the pathogenesis of age-related bone loss and osteoporosis. 
Bonekey Reports, 1, 62. https://doi.org/10.1038/bonek ey.2012.62
Villa-Bellosta,	R.,	Rivera-Torres,	J.,	Osorio,	F.	G.,	Acin-Perez,	R.,	Enriquez,	
J.	A.,	 Lopez-Otin,	C.,	&	Andres,	V.	 (2013).	Defective	extracellular	
pyrophosphate metabolism promotes vascular calcification in a 
mouse model of Hutchinson-Gilford progeria syndrome that is ame-
liorated on pyrophosphate treatment. Circulation, 127(24),	 2442–
2451.	https://doi.org/10.1161/CIRCU	LATIO	NAHA.112.000571
Wakahara,	R.,	Kunimoto,	H.,	Tanino,	K.,	Kojima,	H.,	Inoue,	A.,	Shintaku,	
H.,	 &	 Nakajima,	 K.	 (2012).	 Phospho-Ser727	 of	 STAT3	 regulates	
STAT3 activity by enhancing dephosphorylation of phospho-Tyr705 
largely	 through	 TC45.	Genes to Cells, 17(2),	 132–145.	 https://doi.
org/10.1111/j.1365-2443.2011.01575.x
Xiong,	L.,	Zhao,	K.,	Cao,	Y.	U.,	Guo,	H.-H.,	Pan,	J.-X.,	Yang,	X.,	Ren,	X.,	Mei,	
L., & Xiong, W.-C. (2020). Linking skeletal muscle aging with oste-




Baruffaldi,	 F.,	 Fognani,	 R.,	 Mecca,	 R.,	 Festa,	 A.,	 Papparella,	 S.,	
Paciello,	O.,	Prisco,	F.,	Capanni,	C.,	…	Squarzoni,	S.	(2020).	Long	term	
breeding	of	the	Lmna	G609G	progeric	mouse:	Characterization	of	
homozygous and heterozygous models. Experimental Gerontology, 
130,	110784.	https://doi.org/10.1016/j.exger.2019.110784
Zironi,	 I.,	Gavoci,	E.,	 Lattanzi,	G.,	Virelli,	A.,	Amorini,	F.,	Remondini,	D.,	&	
Castellani, G. (2018). BK channel overexpression on plasma mem-
brane of fibroblasts from Hutchinson-Gilford progeria syndrome. 
Aging (Albany NY), 10(11),	 3148–3160.	 https://doi.org/10.18632/	
aging.101621
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting	Information	section.
How to cite this article: Squarzoni S, Schena E, Sabatelli P, et al. 
Interleukin-6	neutralization	ameliorates	symptoms	in	
prematurely aged mice. Aging Cell. 2021;20:e13285. 
https://doi.org/10.1111/acel.13285
